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INTRODUCTION
Imaging studies play a crucial role in the diagnosis 
of hepatocellular carcinoma (HCC) since pathologic 
confirmation is not always necessary before instituting 
treatment [1-3]. To standardize the use of imaging to 
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Objective: Based on the Liver Imaging Reporting and Data System version 2018 (LI-RADS, v2018), this study aimed to 
analyze LR-5 diagnostic performance for hepatocellular carcinoma (HCC) when threshold growth as a major feature is replaced 
by a more HCC-specific ancillary feature, as well as the frequency of threshold growth in HCC and non-HCC malignancies 
and its association with tumor size.
Materials and Methods: This retrospective study included treatment-naive patients who underwent gadoxetate disodium-
enhanced MRIs for focal hepatic lesions and surgery between January 2009 and December 2016. The frequency of major and 
ancillary features was evaluated for HCC and non-HCC malignancies, and the LR-category was assessed. Ancillary features that 
were significantly more prevalent in HCC were then used to either replace threshold growth or were added as additional major 
features, and the diagnostic performance of the readjusted LR category was compared to the LI-RADS v2018.
Results: A total of 1013 observations were analyzed. Unlike arterial phase hyperenhancement, washout, or enhancing capsule 
which were more prevalent in HCCs than in non-HCC malignancies (521/616 vs. 18/58, 489/616 vs. 19/58, and 181/616 vs. 
5/58, respectively; p < 0.001), threshold growth was more prevalent in non-HCC malignancies than in HCCs (11/23 vs. 
17/119; p < 0.001). The mean size of non-HCC malignancies showing threshold growth was significantly smaller than that 
of non-HCC malignancies without threshold growth (22.2 mm vs. 42.9 mm, p = 0.040). Similar results were found for HCCs; 
however, the difference was not significant (26.8 mm vs. 33.1 mm, p = 0.184). Additionally, Fat-in-nodule was more frequent 
in HCCs than in non-HCC malignancies (99/616 vs. 2/58, p = 0.010). When threshold growth and fat-in-nodule were considered 
as ancillary and major features, respectively, LR-5 sensitivity (73.2% vs. 73.9%, p = 0.289) and specificity (98.2% vs. 98.5%, 
p > 0.999) were comparable to the LI-RADS v2018.
Conclusion: Threshold growth is not a significant diagnostic indicator of HCC and is more common in non-HCC malignancies. 
The diagnostic performance of LR-5 was comparable when threshold growth was recategorized as an ancillary feature and 
replaced by a more HCC-specific ancillary feature.
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diagnose HCC in high-risk patients, the Liver Imaging 
Reporting and Data System (LI-RADS) was developed 
and recently integrated with the American Association 
for the Study of Liver Disease 2018 HCC clinical practice 
guidelines [4]. Since the first LI-RADS was developed 
(v2014), five major features, including arterial phase 
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hyperenhancement (APHE), washout, enhancing capsule, 
diameter, and threshold growth, have been established as 
major features for the initial categorization, which is later 
adjusted according to ancillary features. Among the major 
features, APHE has consistently showed high sensitivity for 
progressed HCC as it indicates the presence of an increased 
intranodular arterial supply during hepatocarcinogenesis [5-
7]. Likewise, washout is also considered a strong predictor 
of HCC, as it indicates decreased portal supply accompanied 
by a progression in the histologic grade of the tumor [7,8]. 
Taken together, these two features show a high specificity 
for HCC in patients with cirrhosis or other risk factors for 
HCC [9,10]. In addition, enhancing capsule, while less 
sensitive, is reported to be specific for HCC, as it is directly 
correlated with either the tumor capsule in progressed HCC 
or a pseudocapsule consisting of mixed fibrous tissue and 
dilated sinusoids [11,12].
These three major features have a strong 
pathophysiological basis in the hepatocarcinogenesis of 
HCC, are well-established in the context of HCC diagnosis, 
and are included in all major imaging-based HCC diagnostic 
algorithms [13-16]. In contrast, the latest LI-RADS version 
2018 (v2018) limits the definition of threshold growth 
to ≥ 50% increase in diameter in ≤ 6 months, which is 
arbitrary and based mainly on expert opinion and an 
attempt to be consistent with the Organ Procurement and 
Transplantation Network (OPTN) algorithm [17]. In addition, 
although interval growth is an important feature for 
radiologists to consider in the diagnosis of any neoplasm, 
the growth rate of HCC can vary widely depending on the 
initial tumor size or histologic differentiation of the lesion 
[18-20]. Furthermore, while threshold growth may be useful 
in reducing false-positive diagnoses by differentiating slow-
growing benign entities, it has limited value in diagnosing 
growing hepatic malignancies, including intrahepatic mass-
forming cholangiocarcinoma (IMCC) or combined HCC-
cholangiocarcinoma (HCC-CCA), which can also occur in 
patients at high-risk for HCC. Indeed, the reported HCC 
tumor doubling time [18,19] overlaps significantly with 
that of IMCC [21]. In a previous study, the removal of 
threshold growth as a major feature was found to cause 
a significant proportion (about 9%) of LR-5 observations 
to be downgraded to LR-4 [22]; however, no study has 
yet evaluated whether replacing threshold growth with an 
ancillary feature would have a similar impact on the LI-
RADS categorization.
Thus, we analyzed LR-5 diagnostic performance when the 
threshold growth as a major feature was replaced by a more 
HCC-specific ancillary feature. Additionally, the frequency 
of threshold growth and associated tumor size in HCC and 
non-HCC malignancies were analyzed.
MATERIALS AND METHODS
Study Population
This study was approved by our Institutional Review Board 
(IRB No. 2020-3696-001), and the requirement for written 
informed consent was waived due to the retrospective 
study design. Using electronic medical records, patients 
with underlying liver cirrhosis or chronic hepatitis B viral 
infection who underwent gadoxetate disodium-enhanced 
MRI between January 2009 and December 2016 for the 
evaluation of focal hepatic observations were identified. 
Patients who 1) underwent surgical resection within 3 
months of the MRI examination, 2) had not received 
treatment for hepatic lesions prior to the MRI examination, 
and 3) were pathologically diagnosed via surgical specimen 
were included. Likewise, patients who 1) had underlying 
congestive hepatopathy or iron-deposition liver disease, 
2) had > 3 hepatic observations, and 3) did not have all 
required MRI protocol imaging were excluded from the 
analysis. For patients with more than one observation, the 
largest observation and its corresponding histopathologic 
diagnosis were used for the analysis [23].
MRI Techniques
All patients underwent MRI examinations using a 3T 
Magnetom Trio Tim (Siemens Medical Solutions), Intera 
Achieva or Ingenia (Philips Medical Systems), or Discovery 
MR750w (GE Medical Systems) MRI scanner [24]. Dynamic 
MRI studies of the liver were performed using 10 mL of 
intravenous gadoxetate disodium (Primovist; Bayer AG) 
at a rate of 1 mL/sec, followed by 20 mL of 0.9% saline 
chaser at the same rate (Spectris Solaris MR Injection 
System; Medrad). T1-weighted three-dimensional gradient-
echo imaging was performed before contrast injection and 
in the arterial phase (18 seconds after aortic enhancement 
using the bolus tracking method), portal venous phase (60 
seconds), delayed phase (90 seconds) transitional phase 
(150 seconds), and hepatobiliary phase (20 minutes after 
contrast agent injection).
Other MRI sequences included an axial dual-echo T1-
weighted breath-hold gradient echo sequence for acquisition 




triggered turbo spin-echo T2-weighted sequence with fat 
saturation, an axial half-Fourier acquisition single-shot 
turbo spin-echo T2-weighted sequence with fat saturation, 
and diffusion-weighted imaging with respiratory-triggered 
single-shot echo planar imaging sequences with b values of 
0, 50, 400, and 800 sec/mm2 or 50, 400, and 800 sec/mm2.
MRI Analysis and the LI-RADS Category Assignment
MR images were randomized and reviewed together by 
two board-certified radiologists with 12 years and 16 years 
of experience in hepatic imaging. If multiple lesions were 
present in one patient, the largest lesion was analyzed. 
However, for surgically confirmed patients, the largest 
lesion, excluding benign LR-1 or LR-2 lesions, was analyzed. 
All MRIs were retrieved and reviewed using a picture 
archiving and communication system (Centricity Radiology 
RA 1000; GE Healthcare). The reviewers analyzed each 
hepatic observation according to the LI-RADS v2018 [25]. 
For the LR-M criteria, both targetoid mass features and 
non-targetoid mass features (i.e., infiltrative appearance, 
marked diffusion restriction, necrosis or severe ischemia, 
and other features considered a non-HCC malignancy by a 
qualified radiologist) were used in the analysis [25]. For 
observations with documented threshold growth, reviewers 
determined the qualifying threshold growth criteria (≥ 50% 
increase in diameter in ≤ 6 months) by retrospectively 
reviewing, measuring and comparing the longest diameter 
of observation on current and prior exams in either the 
transitional or hepatobiliary phase for liver dynamic MRIs 
and the portal venous phase or delayed phase for liver CT. 
Adjustment of Major and Ancillary Features in the 
LI-RADS v2018
Ancillary features with greater frequency in HCC compared 
to non-HCC malignancies in the univariable analysis (i.e., 
χ2 test or Fisher’s exact test) were considered possible 
candidates for new major features. After the relevant 
ancillary features replaced or were added to the major 
features, the final LR-category was then re-evaluated. 
The final diagnosis of the hepatic observation and the 
status of the adjacent non-tumor liver parenchyma were 
obtained from the pathology report. For HCC, tumor grade 
was categorized as I, II, III, and IV based on the nuclear 
grading scheme proposed by Edmondson and Steiner [26]. 
Benign diagnoses were confirmed by surgical pathology (n = 
3), typical imaging features, or stable imaging for at least 2 
years (n = 336) [27]. The fibrosis stage of non-tumor liver 
parenchyma was determined according to the Batts-Ludwig 
scoring system (from F0, no fibrosis to F4, cirrhosis) [28]. 
Statistical Analysis
The patients’ baseline characteristics were compared using 
the χ2 test or the Fisher’s exact test for categorical variables 
and the Student’s t test or Wilcoxon signed-rank test for 
continuous variables. Continuous variables are expressed as 
medians and interquartile ranges. Imaging feature endpoints 
were evaluated on a per-patient basis since one hepatic 
observation for each patient was selected for imaging 
analysis [1]. Estimates and 95% confidence intervals (CIs) 
of diagnostic performance, including sensitivity, specificity, 
positive predictive value, negative predictive value, and 
accuracy, were calculated. The diagnostic performance of 
the adjusted LR-5 was then calculated and compared to that 
of the original LR-5 using the McNemar’s test. The Fisher’s 
exact test was used to evaluate the correlation between 
threshold growth and the Edmondson grade of HCC, and the 
Cochran-Armitage trend test was used to evaluate whether 
the Edmondson grade was higher with or without threshold 
growth. Statistical significance was defined as a two-sided 
p value < 0.05. All statistical analyses were performed 
using MedCalc (version 19.0.7; MedCalc Software) and SPSS 
version 25 (IBM Corp.). 
RESULTS
Patient Characteristics and Pathologic Findings
Of the 1017 patients who were identified based on 
the inclusion and exclusion criteria, four with tumor in 
vein were excluded, resulting in a total of 1013 patients 
who were included in the final analysis (Fig. 1). The 
clinicopathologic characteristics of these 1013 patients (775 
male and 238 female; median age, 56 years) are summarized 
in Table 1. A total of 677 underwent surgery (99 underwent 
wedge resection, 256 and 291 underwent segmentectomy 
and lobectomy, respectively, and 31 underwent liver 
transplantation).
Of the 1013 hepatic observations evaluated, 616 
were HCCs, 58 were non-HCC malignancies (29 IMCC; 24 
cHCC-CCA; 4 metastases from ovarian epithelial cancer, 
pancreatic adenocarcinoma, and colon adenocarcinoma; 
and 1 sarcomatoid cHCC-CCA), and 339 were benign tumors 
(222 hemangioma, 63 dysplastic or regenerative nodules, 
32 focal nodular hyperplasia-like nodules, 16 eosinophilic 
infiltrations, 4 focal fat depositions, 1 focal fat sparing and 
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1 acute and chronic inflammatory lesion). The median sizes 
of HCC and non-HCC malignancies were 29.3 mm and 36.2 
mm, respectively. In addition, of the 405 patients who had 
liver cirrhosis, 230, 173, and 2 had Child Pugh class A, B, 
and C, respectively. 
Frequency of Threshold Growth and Correlation to Size  
of Hepatic Observation
A total of 674 patients had hepatic malignancies. Of 
the 58 patients with non-HCC malignancy and the 616 
with HCCs, 23 (39.7%) and 119 (19.3%) had examinations 
within 6 months of the MRI, respectively (Table 2). Of the 
142 patients with prior examinations, 15 had an exam 
within 1 month of the MRI, 92 had one within 1–3 months 
of the MRI, and 35 had prior exams 3–6 months before the 
MRI. All the patients with exams within 1–6 months of the 
MRI underwent a follow-up MRI to determine the change 
in interval size, while most of the patients who underwent 
an examination within 1 month of the MRI underwent 
MRI following prior CT for further characterization. Among 
the patients with prior exams, threshold growth was more 
frequent in non-HCC malignancies than in HCCs (p < 0.001) 
(Table 3).
The mean size of non-HCC malignancies with threshold 
Treatment-naive patients with high risk of HCC who underwent gadoxetic-acid enhanced MRI
from January 2009 to December 2016 and underwent liver surgery within 3 months from date
of MRI exam (n = 762) and patients with benign heaptic observations proven by typical imaging
features or stability for at least 2 years (n = 336)
Eligible 1017 patients
Final 1013 patients
LR-TIV (n = 4)
LR-M (n = 72)
LR-1 or 2 (n = 309)
LR-3 (n = 32)
5 HCCs (15.6%)
27 benign lesions (84.4%)
  -  DN/RN (n = 13), FNH-like nodule  
(n = 8), hemangioma (n = 5), 
eosinophilic infiltration (n = 1)
451 HCCs (98.5%)
7 non-HCC malignancies (1.5%)
  -  IMCC (n = 1), cHCC-CCA (n = 6)
3 HCCs (75.0%)
1 non-HCC malignancy (25.0%)
  -  cHCC-CCA (n = 1)
31 HCCs (43.1%)
41 non-HCC malignancies (56.9%)
  -  IMCC (n = 24), cHCC-CCA (n = 14), metastasis (3)
309 benign lesions (100%)
  -  Hemangioma (n = 217), FNH-like nodule (n = 24), 
focal fat sparing (n = 1), focal fat deposition (n = 4), 
eosinophilic infiltration (n = 15), DN/RN (n = 48)
129 HCCs (90.8%)
10 non-HCC malignancies (7.0%)
  -  cHCC-CCA (n = 5), IMCC (n = 4), 
metastasis (n = 1)
3 benign lesions (2.1%)
  -  DN/RN (n = 2), acute and chronic 
inflammation (n = 1)
LR-4 (n = 142) LR-5 (n = 458)
Exclusion criteria (n = 81)
  1) > 3 hepatic observations (n = 39)
  2) Congestive hepatopathy or iron-deposition disease (n = 5)
  3) Without all required images of MRI protocol (n = 37)
Fig. 1. Inclusion and exclusion criteria and original final LR-categories of the study population based on LI-RADS v2018. cHCC-CCA = 
combined HCC-choangiocarcinoma, DN = dysplastic nodule, FNH = focal nodular hyperplasia, HCC = hepatocellular carcinoma, IMCC = intrahepatic 




growth (22.2 ± 14.2 mm; range, 9.0–48.6 mm) was 
significantly smaller than the mean size of non-HCC 
malignancies without threshold growth (42.9 ± 28.2 
mm; range, 12.4–120.4 mm) (p = 0.040). There was 
no significant correlation between the size of non-HCC 
malignancies (i.e., < 10 mm, 10–19 mm, and ≥ 20 mm) and 
threshold growth (p = 0.090). For HCC, the mean size of HCC 
with threshold growth (26.8 ± 12.9 mm; range, 11.7–60.7 
mm) was also smaller than the mean size of HCC without 
threshold growth (33.1 ± 18.6 mm; range, 7.0–140.0 mm); 
however, this difference was not statistically significant  
(p = 0.184). Furthermore, smaller HCCs did not trend toward 
greater threshold growth, as there was no significant 
correlation between HCC size and threshold growth (p = 
0.607) (Table 2, Fig. 2). 
Changes to Final LR-Category before and after Follow-Up 
Exam
Of the 142 patients with prior exams, the final LR 
category changed in 11 (7.7%) patients (Supplementary 
Table 1). Four patients (patients #1–#4) showed threshold 
growth on MRI and had their LR categories changed due 
to the added major criterion. In the case of patient #3, 
the presence of threshold growth allowed the final LR-
category to be upgraded to LR-5 on follow-up MRI, even 
though the pathology was later confirmed to be combined 
hepatocellular cholangiocarcinoma, a non-HCC malignancy 
(Fig. 3). The LR categories of six patients (patients #5–10) 
were upgraded since the tumor size had increased ≥ 20 mm 
on MRI. One patient (patient #11) had their LR-category 
upgraded from LR-3 to LR-4 due to ancillary features such 
as transitional phase hypointensity and hepatobiliary phase 
hypointensity on MRI, which could not be assessed in prior 
CT examinations. 
Frequency of Major and Ancillary Features in HCC and 
Non-HCC Malignancy
As expected, APHE, washout, and enhancing capsule 
were more frequently observed in HCC than in non-HCC 
malignancies with a significant difference (p < 0.001) 
(Table 3). 
Concerning the ancillary features, targetoid mass features 
and corona enhancement were significantly more common 
in non-HCC malignancies. Of the ancillary features favoring 
HCC in particular, transitional phase hypo-intensity and fat-
containing nodules were more frequently observed in HCC.
Table 1. Clinical-Pathologic Characteristics of Patients and 
Hepatic Observations
Characteristics Value
Patients (n = 1013)




Cause of liver disease
Hepatitis B virus 875 (86.4)
Alcohol 78 (7.7)








Lesions (n = 1013)
Median size, mm* 24.1 (14.0–35.9)
HCC 29.3 (21.8–42.9)
Non-HCC malignancies 36.2 (24.0–46.6)
Benign lesions 11.0 (10.0–18.0)
Size subgroup, mm









Sarcomatoid cHCC-CCA 1 (1.7)
Benign tumors 339 (33.5)
Hemangioma 222 (65.5)
Dysplastic or regenerative nodule 63 (18.6)
FNH-like nodule 32 (9.4)
Eosinophilic infiltration 16 (4.7)
Focal fat deposition 4 (1.2)
Focal fat sparing 1 (0.3)
Inflammatory pseudotumor 1 (0.3)
Pathologically confirmed liver fibrosis (n = 677)
Cirrhosis (grade 4) 405 (59.8)
Septal fibrosis (grade 3) 134 (19.8)
Periportal fibrosis (grade 2) 102 (15.1)
Portal fibrosis (grade 1) 36 (5.3)
Median time interval between MRI and
  pathologic diagnosis, day*
13 (7–22)
Unless stated otherwise, data are number of patients or 
observations with the percentage in parentheses. *Data are 
presented as median (interquartile range). cHCC-CCA = combined 
HCC-choangiocarcinoma, FNH = focal nodular hyperplasia, HCC = 
hepatocellular carcinoma, IMCC = intrahepatic mass-forming 
cholangiocarcinoma, NASH = non-alcoholic steatohepatitis
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Diagnostic Performance of Adjusted LR-5 after Modifying 
Major Features Using Ancillary Features
The final LR categories of the 1013 patients based on 
the LI-RADS v2018 were as follows: 72 LR-M, 309 LR-2, 
32 LR-3, 142 LR-4, and 458 LR-5 (Fig. 1). Based on these 
categorizations, LR-5 had a sensitivity of 73.2% and a 
specificity of 98.2% for HCC (Table 4). 
Although transitional phase hypointensity was 
significantly different between non-HCC malignancy and 
HCC (p = 0.012), this finding was high in both non-HCC 
malignancies (47/58, 81.0%) and HCC (562/616, 91.2%) 
and was therefore not considered a useful imaging feature 
for the differential diagnosis of HCC. Since fat-in-nodule 
were significantly more frequent in HCCs than in non-HCC 
malignancies (p = 0.010) and were only seen in 3.4% of 
non-HCC malignancies, it was selected as a possible major 
feature.
After adding fat-in-nodule as a major feature, four LR-4 
observations were upgraded to LR-5 and the LR-5 sensitivity 
increased non-significantly to 73.9% (p = 0.125), while no 
change was noted for the specificity (Table 4). 
When threshold growth was replaced by fat-in-nodule as 
Table 2. Correlation between Observation Size and Theshold Growth
# of Patients with 






HCC, mm (n = 616)
< 10 3/8 (37.5) 0/3 (0.0) 3/3 (100.0) 0.360 0.607
10–19 27/114 (23.7) 6/27 (22.2) 21/27 (77.8)
20 89/494 (18.0) 11/89 (12.4) 78/89 (87.6)
Non-HCC malignancies, mm (n = 58)
< 10 3/3 (100.0) 3/3 (100.0) 0/3 (0.0) 0.199 0.090
10–19 4/6 (66.7) 2/4 (50.0) 2/4 (50.0)
20 16/49 (32.7) 6/16 (37.5) 10/16 (62.5)
*Fisher’s exact test, †Cochran-Armitage’s trend test. HCC = hepatocellular carcinoma




(n = 58) (%)
HCC 
(n = 616) (%)
P*
Major features
APHE  674 18 (31.0) 521 (84.5) < 0.001
WO 674 19 (32.7) 489 (79.3) < 0.001
Enhancing capsule 674 5 (8.6) 181 (29.4) < 0.001
Threshold growth 142 11/23 (47.8) 17/119 (14.2) < 0.001
Ancillary features
Subthreshold growth   53 5/7 (71.4) 36/46 (78.3) 0.704
Targetoid mass features 674 32 (55.2) 27 (4.4) < 0.001
Corona enhancement 674 22 (37.9) 134 (21.8) 0.005
Fat sparing in solid mass 674 1 (1.7) 13 (2.1) 0.844
Restricted diffusion 674 55 (94.8) 585 (95.0) 0.963
Mild to moderate T2 hyperintensity 674 53 (91.4) 579 (94.0) 0.431
Iron sparing in solid mass 674 0 (0) 3 (0.5) > 0.999
TP hypointensity 674 47 (81.0) 562 (91.2) 0.012
HBP Hypointensity 674 54 (93.1) 574 (93.2) 0.982
Nonenhancing capsule 674 2 (3.4) 27 (4.4) > 0.999
Nodule-in-nodule 674 0 (0) 7 (1.1) > 0.999
Mosaic architecture 674 2 (3.4) 50 (8.1) 0.203
Fat-in-nodule 674 2 (3.4) 99 (16.1) 0.010
Blood product 674 2 (3.4) 56 (9.1) 0.217
*χ2 test or Fisher’s exact test. APHE = (nonrim) arterial phase hyperenhancement, HBP = hepatobiliary phase, HCC = hepatocellular 




a major feature and threshold growth was considered an 
ancillary feature, seven LR-4 observations were upgraded 
to LR-5, while three LR-5 observations were downgraded 
to LR-4. Under these conditions, LR-5 sensitivity and 
specificity were 73.9% (p = 0.289) and 98.5% (p > 0.999), 
respectively.
Correlation between Observation Size and Edmondson 
Grade of HCC and Threshold Growth 
No significant correlation was found between threshold 
growth and Edmondson grade of HCC (p = 0.364), and no 
trend was found in threshold growth for either low or high 
Edmondson grade of HCC (p = 0.637) (Table 5).
DISCUSSION
The results of our study indicate that when fat-in-nodule 
replaced threshold growth as a major feature, both LR-5 
specificity and sensitivity were slightly improved, although 
there was no statistically significant difference. When fat-
in-nodule was added as an additional major feature, the 
sensitivity of LR-5 was slightly higher without affecting 
the specificity. The presence of threshold growth was 
higher in non-HCC malignancies than in HCC, and non-HCC 
malignancies with threshold growth were smaller in size 
than those not exhibiting threshold growth.
Intuitively, the presence of threshold growth could be 
affected by the initial tumor size because the definition 
of ≥ 50% increase in diameter in ≤ 6 months can be 
more easily achieved by smaller observations than larger 
observations. Previous results have also shown that 
smaller HCCs usually increase in size faster than larger 
ones, although there are many other factors related to the 
growth rate of HCC [18,19]. In our study, this trend was 
more dominant in non-HCC malignancies, although the 
difference was not statistically significant. However, when 
excluding HCCs < 10 mm in size, threshold growth was also 
more frequent in smaller HCCs (10–19 mm) than in larger 
HCCs (≥ 20 mm), although this difference was also not 
significant. A possible reason for this result could be the 
Fig. 2. A 61-year-old female with Edmonson grade II hepatocellular carcinoma is presented. 
A-H. A liver dynamic CT (A, B) taken on January 2, 2009 with (A) non-rim APHE in the arterial phase and (B) washout in the portal venous 
phase. A gadoxetate-enhanced liver dynamic MRI (C-H) taken on February 27, 2009 (about 2 months after the prior exam) with (C) APHE in the 
late arterial phase, (D) washout with capsular enhancement in the portal venous phase, (E) transitional phase hypointensity, (F) hepatobiliary 
phase hypointensity, (G) diffusion restriction in diffusion-weighted imaging and (H) moderate T2 hyperintensity in T2-weighted imaging. This 
observation’s longest diameter measured 12 mm on liver dynamic CT and 15 mm on gadoxetate-enhanced MRI and thus threshold growth was not 
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low proportion (n = 82, 8.1%) of observations < 10 mm in 
size, thus explaining the low statistical power. Additionally, 
the proportion of small HCCs (< 10 mm) was less than the 
proportion of small non-HCC malignancies (< 10 mm), since 
many of the small HCCs were treated using non-surgical 
methods such as radiofrequency ablation and transarterial 
chemoembolization.
Fatty metamorphosis in HCCs has been reported in 
approximately 16–18% of HCC cases [29], which is 
consistent with our results (16.1% in HCC), and it was more 
frequently observed in HCC than in non-HCC malignancies 
(3.4%). In our study, fat-in-nodule were a more HCC-
specific feature than threshold growth, and the diagnostic 
performance of LR-5 for HCC when fat-in-nodule replaced 
threshold growth as a major feature was comparable to that 
obtained using the current LI-RADS v2018. However, our 
results showed that when fat-containing nodules replaced 
threshold growth as a major feature, neither LR-5 sensitivity 
nor specificity were significantly higher than those of the 
original LR-5. Similarly, when fat-in-nodule was added as a 
major feature, no reduction in LR-5 specificity was noted, 
while the LR-5 sensitivity increased non-significantly 
by approximately 0.7%. However, fatty metamorphosis 
occurs more frequently in early-stage HCCs, especially in 
those < 15 mm in size [30]. Thus, the proportion of early- 
and progressed HCCs in the study population could have 
Fig. 3. A 34-year-old male with combined hepatocellular-cholangiocarcinoma is presented. 
A-F. An abdominal CT in the portal venous phase (A) obtained on December 27, 2008 shows a focal hypodense lesion measuring < 1 cm at its 
longest diameter. A gadoxetate-enhanced MRI taken on June 7, 2009 (less than six months after the prior exam) in the late arterial phase (B), 
portal venous phase (C), and hepatobiliary phase (D), and with T2-weighted imaging (E) and diffusion-weighted imaging (F). This observation 
shows non-rim enhancement in the arterial phase without definite washout, hepatobiliary phase hypointensity, moderate T2 hyperintensity 
and diffusion restriction. This observation measured 2.3 cm at its longest diameter on gadoxetate-enhanced MRI, thus showing the presence of 










affected the prevalence of fat-containing nodules. 
Regardless, our findings demonstrate a diagnostic 
performance comparable to the original LR-5 when threshold 
growth is replaced by a more HCC-specific ancillary feature, 
which raises the question of whether threshold growth has 
enough scientific evidence to remain a major feature. One 
significant limitation of threshold growth is that it cannot 
be applied in the diagnosis of HCC when previous CT or MRI 
examinations are not available [2]. In our study, 43.2% 
(438/1013) of all patients had prior exams, of which 29.3% 
(142/483) had hepatic malignancies, and 19.7% (28/142) 
showed threshold growth. In the case of HCC, 19.3% 
(119/616) had prior exams, wherein 14.2% (17/119) showed 
threshold growth, which was close to the reported 14.7% in a 
previous study where prior exams were available in 66.4% of 
all patients (n = 489 observations) [22]. However, Chernyak 
et al. [22] acknowledged that their study period was too 
short to include many first-time patients, thus explaining 
the relatively larger proportion of patients with prior exams, 
acknowledging this might have inflated the importance 
of threshold growth. However, the small proportion of 
observations with the LI-RADS categorization changes due to 
threshold growth was similar between the studies.
Previously, it has been suggested that removing threshold 
growth as a major feature would lead to the under-
diagnosis of aggressive, rapidly growing HCCs, which, if 
left untreated, would be the most harmful to patients 
[22]. While the histological differentiation of HCC is 
often heterogeneous, tumor doubling time is reported to 
correlate significantly with histological differentiation 
of HCC, with more rapid tumor growth reported in poorly 
differentiated HCCs [20,31,32]. However, our results showed 
no significant correlation between Edmondson grade of 
HCC and the presence of threshold growth. Moreover, our 
results showed that HCCs with threshold growth were not 
correlated with higher Edmondson grade tumors compared 
to those without threshold growth. Thus, removing 
threshold growth as a major feature and incorporating 
it into ancillary features alongside subthreshold growth 
may have a marginal impact on the exclusion of rapidly 
growing HCCs. Although threshold growth can be useful 
for differentiating benign observations, such as dysplastic 
or regenerative nodules and focal nodular hyperplasia-like 
nodules from primary hepatic malignancy, it has a limited 
role in differentiating other hepatic malignancies from HCC 
[33-35]. However, benign lesions (i.e., LR-1 and LR-2) are 
Table 4. Sensitivity, Specificity, Accuracy, PPV and NPV of HCC Under Various Adjustment of Major and Ancillary Features in LI-
RADS v2018






















































Data are percentages with the number of lesions in parentheses. Numbers in brackets are the 95% confidence intervals. *Threshold 
growth was considered as an ancillary feature, †p value after comparing sensitivity to sensitivity of original LR-5 using McNemar’s test, 
‡p value after comparing specificity to specificity of original LR-5 using McNemar’s test. HCC = hepatocellular carcinoma, LI-RADS = Liver 
Imaging Reporting and Data Systems, NPV = negative predictive value, PPV = positive predictive value
Table 5. Correlation between Edmondson Grade of Hepatocellular Carcinoma and Threshold Growth
Edmonson Grade (%)
P* P†
1 2 3 4
Threshold growth 3 (17.7) 10 (58.8) 4 (23.5) 0 (0) 0.364 0.637
*Fisher’s exact test, †Cochran-Armitage’s trend test. 
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often excluded before categorizing a hepatic observation 
as LR-3, -4, or -5 based on the LI-RADS v2018 algorithm; 
therefore, the presence of threshold growth may have a 
limited role in the diagnosis of HCC. In our study, two of 
the 63 (3.2%) dysplastic or regenerative nodules showed 
threshold growth and were categorized as LR-4, while the 
other nodules were categorized as LR-2 or LR-3. However, 
both nodules would still have been categorized as LR-4 
via upgrade using threshold growth as an ancillary feature. 
By keeping threshold growth as an ancillary feature, LR-3 
observations can still be upgraded to LR-4, which improves 
the diagnostic performance of LR-4 while also preventing 
non-HCC malignancies from being assigned to LR-5, thus 
allowing for high LR-5 specificity for HCC.
This study has several limitations. First, there may 
have been selection bias due to the retrospective 
study design and the inclusion of hepatic malignancies 
histopathologically confirmed through surgical resection. 
While only surgically resected hepatic malignancies 
were included in this study, pathological confirmation 
was necessary to accurately evaluate the prevalence of 
both major and ancillary features, especially threshold 
growth, between HCCs and non-HCC malignancies since 
some LR-4 and/or LR-5 non-HCC malignancies may have 
been categorized as HCCs using imaging findings alone. 
Second, imaging analysis was performed by two radiologists 
in consensus; thus, no interobserver agreement was 
determined. Third, slightly more than half of all included 
observations did not have prior exams since this study 
was conducted in a tertiary hospital, and the number of 
patients with prior exams was smaller than that reported 
in a previous study [22]. Fourth, fat-in-nodule noted on 
MRI were not confirmed by pathology since only fatty 
changes at the cellular level were reported. Lastly, while 
we used fat-in-nodule as an example to show that similar 
diagnostic performance can be obtained when an ancillary 
feature is added to or replaces threshold growth, further 
investigation is required before the actual application of 
fat-in-nodule as a major feature, as it may not be the most 
appropriate HCC-specific feature. Moreover, various factors, 
including the possibility of over-categorizing hypervascular 
tumors with fatty components such as hepatic adenoma or 
angiomyolipoma, and benign entities, such as dysplastic or 
regnerative nodules, must be considered before recognizing 
fat-in-nodules as a major feature.
In conclusion, while threshold growth can occur in both 
HCC and non-HCC malignancies, it is more common in non-
HCC malignancies and can be affected by the initial tumor 
size. Radiologists should be cautious when upgrading LR-4 
observations to LR-5 using threshold growth as the sole 
determining factor. When threshold growth was considered 
an ancillary feature and a different ancillary feature more 
specific to HCC was added or replaced threshold growth as 
a major feature, no significant reduction in LR-5 diagnostic 
performance was observed compared to the LI-RADS v2018.
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